German researchers found no significant differences after three years in ocular or non-ocular adverse events in diabetic macular edema patients who either had initial as-needed ranibizumab injections or laser surgery. Patients in the ranibizumab-only treatment gained higher mean best-corrected visual acuity compared with those who had ranibizumab plus surgery and surgery-only treatments. The results were presented at the European Association for the Study of Diabetes meeting.

Related Summaries